Renato Zambello
A5066814162- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Peptidase Inhibition and Analysis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- HIV Research and Treatment
- Acute Myeloid Leukemia Research
- Sarcoidosis and Beryllium Toxicity Research
- Chronic Myeloid Leukemia Treatments
- Viral-associated cancers and disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- T-cell and Retrovirus Studies
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Acute Lymphoblastic Leukemia research
- HIV/AIDS drug development and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peripheral Neuropathies and Disorders
- Heat shock proteins research
- CNS Lymphoma Diagnosis and Treatment
University of Padua
2016-2025
Veneto Institute of Molecular Medicine
2016-2025
Azienda Ospedaliera di Padova
2014-2023
Sarah Cannon
2023
Institute of Molecular Medicine
2019-2022
Fondazione Gimema Onlus
2009-2021
Multiple Myeloma Research Foundation
2021
March of Dimes
2021
The University of Texas MD Anderson Cancer Center
2019
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low molecular weight heparin (LMWH) for preventing thromboembolism in myeloma treated thalidomide-based regimens. Patients and Methods A total 667 previously untreated who received thalidomide-containing regimens had no clinical indication...
Bortezomib-melphalan-prednisone (VMP) has improved overall survival in multiple myeloma. This randomized trial compared VMP plus thalidomide (VMPT) induction followed by bortezomib-thalidomide maintenance (VMPT-VT) with patients newly diagnosed myeloma.We randomly assigned 511 who were not eligible for transplantation to receive VMPT-VT (nine 5-week cycles of VMPT 2 years VT maintenance) or without maintenance).In the initial analysis a median follow-up 23 months, complete response rate from...
B cell chronic lymphocytic leukemia (B-CLL) is a neoplastic disorder characterized by accumulation of lymphocytes due to uncontrolled growth and resistance apoptosis. Analysis cells freshly isolated from 40 patients with demonstrated that the Src kinase Lyn, switch molecule couples receptor downstream signaling, displays anomalous properties. Lyn remarkably overexpressed at protein level in leukemic as compared normal lymphocytes, substantial aliquot anomalously present cytosol. Whereas...
B cell chronic lymphocytic leukemia (B-CLL) is a neoplastic disorder characterized by accumulation of lymphocytes due to uncontrolled growth and resistance apoptosis. Analysis cells freshly isolated from 40 patients with demonstrated that the Src kinase Lyn, switch molecule couples receptor downstream signaling, displays anomalous properties. Lyn remarkably overexpressed at protein level in leukemic as compared normal lymphocytes, substantial aliquot anomalously present cytosol. Whereas...
The ability of NK cells to kill a wide range tumor or virally infected target as well normal allogeneic T cell blasts appears depend upon the concerted action multiple triggering receptors. In this study, using two specific monoclonal antibodies [(mAb) MA152 and LAP171], we identified receptor expressed at surface dimer approximately 80 kDa (NKp80). NKp80 is by virtually all fresh activated minor subset characterized CD56 antigen. expression was also detected in CD3– 6 / 10 CD3+ large...
A multiparameter analysis, which included the evaluation of clinical features, cell morphology, karyo-type, phenotypic and functional immunologic findings, T-cell receptor beta-chain configuration was performed on 34 patients with lymphoproliferative disease granular lymphocytes (LDGL). The two-fold aim study to identify most useful tools that would more accurately characterize these deal problem classifying disorders. data presented in this article suggest a single parameter may not be...
The combination of bendamustine (B) and rituximab (R) is efficacious, with favorable toxicity in mantle-cell lymphoma (MCL). In this phase II study, we combined cytarabine R B (R-BAC) patients MCL age ≥ 65 years who were previously untreated or relapsed refractory (R/R) after one prior immunochemotherapy treatment.In stage one, established the maximum-tolerated dose (MTD) R-BAC. two, received (375 mg/m(2) intravenously [IV] on day 1), (70 IV days 2 3), (MTD to 4) every 28 for four six...
Lymphoproliferative disease of granular lymphocytes (LDGL) is a recently recognized, relatively rare atypical lymphocytosis characterized by the presence over 2000 with cytoplasmic azurophilic granules/mm3 in peripheral blood. The clinical course heterogeneous, varying from spontaneous regression to progressive, malignant disease. As consequence, intervention not standardized. In worldwide multicenter study, authors observed 151 patients LDGL for mean follow-up time 29 months. Forty-three...
Treatment of secondary CNS dissemination in patients with aggressive lymphomas remains an important, unmet clinical need. Herein, we report the final results a multicenter phase II trial addressing new treatment for lymphoma based on encouraging experiences high doses antimetabolites primary and rituximab plus high-dose sequential chemoimmunotherapy (R-HDS) relapsed lymphoma.HIV-negative B-cell involvement at diagnosis or relapse, age 18 to 70 years, Eastern Cooperative Oncology Group...
8002 Background: High and comparable rates of MRD negativity were seen in NDMM pts after 4 28-day induction cycles with KRd followed by ASCT consolidation (KRd_ASCT_KRd) 12 (KRd12), showing the superiority both regimens over KCd induction-ASCT-KCd (KCd-ASCT-KCd) (Gay F ASH 2018). Here we evaluated benefit KRd_ASCT_KRd vs KRd12 specific subgroups pts. Methods: 474 ≤65 years randomized to or KCd_ASCT_KCd. We compared rate ≥VGPR, ≥CR, sCR, (centralized, second generation flow cytometry,...
Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopoietic stem-cell transplantation (HSCT) secondary
High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma are a marker aggressive disease. We aimed to confirm the prognostic impact and identify possible cutoff value CTC-high for prediction progression-free survival (PFS) overall (OS), context concomitant risk features minimal residual disease (MRD) achievement.CTC were analyzed at diagnosis two-tube single-platform flow cytometry (sensitivity 4 × 10-5) enrolled multicenter randomized FORTE clinical trial...
Abstract T cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder of mature, clonally expanded cells, where somatic-activating STAT3 mutations are common. Although T-LGLL has been described as chronic response to an antigen, the function non-leukemic immune system in this largely uncharacterized. Here, by utilizing single-cell RNA and receptor profiling (scRNA+TCRαβ-seq), we show that irrespective mutation status, clonotypes more cytotoxic exhausted than...
Not available.
Abstract The accumulation of T cells and monocytes at sites ongoing inflammation represents the earliest step in series events that lead to granuloma formation sarcoidosis. In this study, we evaluated pulmonary production IFN-inducible protein 10 (IP-10), a CXC chemokine stimulates directional migration activated cells. Striking levels IP-10 were demonstrated bronchoalveolar lavage (BAL) fluid 24 patients with sarcoidosis lymphocytic alveolitis, as compared inactive disease or control...